Viatris Inc. reports results for the quarter ended June 30 - Earnings Summary
Viatris Inc. reports results for the quarter ended June 30 - Earnings Summary
Viatris Inc. VTRS.OQ reported quarterly adjusted earnings of 69 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 62 cents. The mean expectation of eight analysts for the quarter was for earnings of 60 cents per share. Wall Street expected results to range from 57 cents to 62 cents per share.
Revenue rose 4.9% to $3.76 billion from a year ago; analysts expected $3.68 billion.
Viatris Inc.'s reported EPS for the quarter was a loss of 10 cents.
The company reported a quarterly loss of $118.8 million.
Viatris Inc. shares had risen by 11.1% this quarter and gained 41.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 1.5% in the last three months.
In the last 30 days, three analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Viatris Inc. is $18.00, about 1.9% above its last closing price of $17.65
This summary was machine generated from LSEG data August 6 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 0.60 | 0.69 | Beat |
Mar. 31 2026 | 0.50 | 0.59 | Beat |
Dec. 31 2025 | 0.53 | 0.57 | Beat |
Sep. 30 2025 | 0.62 | 0.67 | Beat |
Recent news on Viatris
See all newsBrief: Viatris Receives U.S. FDA Approval For Ryzumvi® For The Treatment Of Presbyopia
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Deals of the day-Mergers and acquisitions
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal